Register for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
RocheSwiss diversified pharma. Carmot acquisition (December 2023, $2.7B) brought CT-388 (about 23% placebo-adjusted weight loss at 48 weeks Phase 2), CT-996 oral, and CT-868. Zealand licensing deal ($1.65B) added petrelinitide amylin program.
All metrics are vertically resized to show how they've changed over time. They're not on the same Y-axis. This chart is meant to compare trends, not values.
Values normalized to 0-100 scale for comparison. Hover for actual values.